Smiths Group PLC (FRA:QS2A)

€ 20.8 0 (0%) Market Cap: 7.11 Bil Enterprise Value: 7.37 Bil PE Ratio: 23.99 PB Ratio: 2.66 GF Score: 84/100

Full Year 2024 Smiths Group PLC Earnings Call Transcript
Sep 24, 2024

€20.5 (-3.85%)

Earnings
Half Year 2024 Smiths Group PLC Earnings Presentation Transcript
Mar 26, 2024
Smiths Group PLC John Crane Deep Dive Presentation Transcript
Nov 30, 2023
Full Year 2023 Smiths Group PLC Earnings Presentation Transcript
Sep 26, 2023
Half Year 2023 Smiths Group PLC Earnings Presentation Transcript
Mar 24, 2023
Smiths Group PLC Annual Shareholders Meeting Transcript
Nov 16, 2022
Smiths Group PLC Capital Markets Event Transcript
Nov 10, 2022
Full Year 2022 Smiths Group PLC Earnings Presentation Transcript
Sep 23, 2022
Half Year 2022 Smiths Group PLC Earnings Call Transcript
Mar 25, 2022

€17.73 (-3.30%)

Earnings
Smiths Group PLC Capital Markets Day Part 2 - Q&A Session Transcript
Nov 18, 2021
Smiths Group PLC Capital Markets Day Part 1 Transcript
Nov 17, 2021
Full Year 2021 Smiths Group PLC Earnings Presentation Transcript
Sep 28, 2021
ICU Medical Inc to Acquire Smiths Medical Division from Smiths Group PLC Call Transcript
Sep 08, 2021
Smiths Group PLC to Discuss Superior Transaction for Sale of Smiths Medical to ICU Medical Inc Call Transcript
Sep 08, 2021
Smiths Group PLC to Discuss Agreement for the Sale of Smiths Medical to TA Associates Management LP Call Transcript
Aug 03, 2021
Half Year 2021 Smiths Group PLC Earnings Presentation Transcript
Mar 26, 2021
Full Year 2020 Smiths Group PLC Earnings Presentation Transcript
Sep 24, 2020
Q2 2020 Smiths Group PLC Trading Statement Call Transcript
Jun 30, 2020
Half Year 2020 Smiths Group PLC Earnings Presentation Transcript
Apr 06, 2020
Smiths Group PLC Annual Shareholders Meeting Transcript
Nov 13, 2019
Full Year 2019 Smiths Group PLC Earnings Presentation Transcript
Sep 20, 2019
Half Year 2019 Smiths Group PLC Earnings Presentation Transcript
Mar 22, 2019

Smiths Group PLC to Discuss Agreement for the Sale of Smiths Medical to TA Associates Management LP Call Transcript

Aug 03, 2021 / 09:00AM GMT

Release Date Price: €16.7 (-7.99%)

Transcript

Operator

Good day, and thank you for standing by. Welcome to the Smiths Group plc call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Paul Keel. Please go ahead.

Paul A. Keel

Smiths Group plc - CEO & Executive Director

Good morning, everyone, and thank you for joining us today. For those of you, who I've not yet met, my name is Paul Keel, and I had the honor of joining this great company as CEO in May. I am joined today by our CFO, John Shipsey. We are pleased to announce that we have entered into a definitive agreement to sell Smiths Medical for a price of USD 2.3 billion plus an additional $0.2 billion contingent on future performance of Smiths Medical. This delivers on the commitment we made to separate this business and focuses our attention, resources and capital on the many exciting opportunities available to us in Smiths' attractive industrial technology core. Let me walk you through the details of today's announcement, beginning on Slide 3.

We took the decision to separate Medical in order to simplify

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.